BioCryst Pharmaceuticals
BCRX
BCRX
123 hedge funds and large institutions have $817M invested in BioCryst Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 40 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
6% more funds holding
Funds holding: 116 → 123 (+7)
0.78% more ownership
Funds ownership: 91.56% → 92.34% (+0.78%)
23% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 40
Holders
123
Holding in Top 10
5
Calls
$2.1M
Puts
$1.44M
Top Buyers
| 1 | +$11.5M | |
| 2 | +$5.37M | |
| 3 | +$3.51M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.83M |
| 5 |
EU
Emory University
Atlanta,
Georgia
|
+$2.56M |
Top Sellers
| 1 | -$6.15M | |
| 2 | -$4.83M | |
| 3 | -$3.8M | |
| 4 |
Millennium Management
New York
|
-$3M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.87M |